糖基化
双特异性抗体
聚糖
抗体
碎片结晶区
岩藻糖
糖组学
内糖苷酶
免疫球蛋白G
计算生物学
化学
糖蛋白
生物
免疫学
单克隆抗体
生物化学
作者
Yusuke Mimura,Toshihiko Katoh,Radka Saldova,Róisín O’Flaherty,Tomonori Izumi,Yuka Mimura‐Kimura,Toshiaki Utsunomiya,Yoichi Mizukami,Kenji Yamamoto,Tsuneo Matsumoto,Pauline M. Rudd
出处
期刊:Protein & Cell
[Springer Science+Business Media]
日期:2017-06-08
卷期号:9 (1): 47-62
被引量:216
标识
DOI:10.1007/s13238-017-0433-3
摘要
Glycosylation of the Fc region of IgG has a profound impact on the safety and clinical efficacy of therapeutic antibodies. While the biantennary complex-type oligosaccharide attached to Asn297 of the Fc is essential for antibody effector functions, fucose and outer-arm sugars attached to the core heptasaccharide that generate structural heterogeneity (glycoforms) exhibit unique biological activities. Hence, efficient and quantitative glycan analysis techniques have been increasingly important for the development and quality control of therapeutic antibodies, and glycan profiles of the Fc are recognized as critical quality attributes. In the past decade our understanding of the influence of glycosylation on the structure/function of IgG-Fc has grown rapidly through X-ray crystallographic and nuclear magnetic resonance studies, which provides possibilities for the design of novel antibody therapeutics. Furthermore, the chemoenzymatic glycoengineering approach using endoglycosidase-based glycosynthases may facilitate the development of homogeneous IgG glycoforms with desirable functionality as next-generation therapeutic antibodies. Thus, the Fc glycans are fertile ground for the improvement of the safety, functionality, and efficacy of therapeutic IgG antibodies in the era of precision medicine.
科研通智能强力驱动
Strongly Powered by AbleSci AI